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PERSPECTIVES IN CLINICAL NEPHROLOGY
Heparin lowers blood pressure: Biological and clinical
perspectives
Biological perspective
The term heparin refers to a set of macromolecules produced
by mast cells as secreted products [1]. These have been reported
to include a heterogenous group of molecular structures and
substituents called proteoglycans [2]. The basic structure of these
proteoglycans includes a core protein onto which are bound
numerous sulfated and/or acetylated polysaccharide chain sub-
units called glycosaminoglycans (GAGs). Such substituents pro-
vide these molecules with the major biological properties attrib-
uted to "heparin" [3]. Some biological properties of heparin are
well-known, while some others are relatively less-known. One of
the well-known properties is the prevention and/or regulation of
blood clotting and, therefore, thrombosis. Among the unknown or
less well-known biological properties is the reduction of elevated
blood pressure. In 1978, Mandal and colleagues [4] observed
significant reduction of mean arterial pressure in spontaneously
hypertensive rats after four weeks treatment with heparin in-
tended for amelioration of glomerular thrombosis. This finding on
the blood pressure lowering effect of heparin was subsequently
confirmed in several studies by this group [5—81. Other less
well-known functions of heparin and related glycoproteins include
the binding of growth factors, and regulation of cellular growth/
differentiation patterns [9, 10].
All of these molecules, proteoglycans, have similar general
structural features, while also having a high degree of variability
[11]. This variability imparts a large information carrying capacity
to these molecules. Proteoglycan structure begins with a core
protein, which may contain a few or many GAG binding sites that
have specific amino acid sequences [12, 13]. These sites are
substituted to various degrees with side chain polysaccharides
made up of repeating hexosamine and hexuronic acid subunits.
These can include both acetylated and sulfated components
organized in patterns which impart localized regions of high
anionic charge alternating with neutral segments [14]. The relative
arrangement of these charged and uncharged areas provides the
molecule with additional information carrying ability. As a result
of the high anionic charge imparted by sulfated GAGs, heparin is
the most negatively charged biomolecule made by mammals [15].
Heparin has more sulfate radicals than other GAGs: 2.5 sulfate
residues per disaccharide unit which imparts high biological
activity [16].
In addition to heparin, several physically related proteoglycans
including heparan sulfate, dermatan sulfate, chondroitin sulfate,
and hyaluronic acid have been identified in association with cell
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surfaces and with components of the extracellular matrix [17].
These molecules are found in surface coatings of many cells and
have varying compositions of substituents which may change in
relation to growth or differentiation status [18—20]. These mole-
cules function to bind and transduce signals which range from
soluble growth factors like fibroblast growth factor, to static
extracellular support molecules like collagen [21—23]. The term
heparan sulfate is applied to a set of these molecules associated
with the surface of many cells. These may have several different
core proteins, but generally have similar GAGs, although the
subunit arrangement and relative degree of sulfation/acetylation
can vary [24, 25]. Some forms of heparan sulfate core protein
include a transmembrane region which firmly anchors these
proteoglycans within the membrane. Other forms include an outer
proteoglycan linked to an integral membrane protein by a phos-
phoinositol linkage [26]. This molecule is easily susceptible to
cleavage and so can provide both an integral membrane trans-
ducer as well as a potentially circulating signal molecule.
What functions can be assigned to this interesting group of
molecules? Based on diversity of charge organization, the signal
carrying and/or transducing potential of heparin and heparin-like
molecules is apparent. Indeed, signal transduction is precisely the
nature of functions already defined for some cell-associated
heparan sulfates [13]. It has been shown that binding of fibronec-
tin to surface heparan sulfate produces a signal through the cell
membrane which directly connects to the cytoskeleton [27], and
from there the signal can be transduced to the nucleus, modifying
gene expression directly. Other examples of this arrangement
include binding of circulating growth factors at the cell surface
followed by transmembrane signal transduction [28, 29] or direct
internalization of the entire receptor/ligand complex followed by
internal signal processing [30, 31].
Soluble forms of heparin have been noted to have at least two
major systemic functions. These are prevention of thrombosis [32,
33] and the reduction of elevated blood pressure. The mecha-
nism(s) of the second major systemic function of heparin, the
lowering of blood pressure, has not yet been fully elucidated
[4—8].
Insightful developments on the blood pressure lowering effect
of hepann
The second major effect of heparin, which is the focus of
current research in several laboratories including our own, is the
lowering of blood pressure. For almost a decade and a half,
Mandal and collaborators [4—8] have repeatedly shown that
chronic administration of heparin (200 to 300 U s.c.) given daily
for a period of four weeks consistently lowers blood pressure in
spontaneously hypertensive rats (SHR) and in Goldblatt hyper-
tensive rats. This antihypertensive effect is hemodynamically
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Table 1. Body fluid determinations in SHR
Extracellular
Group
Plasma volume
mlii00 g
Blood volume
m11100g
fluid volume
m11100 g
Control 3.84 0.18 7.23 0.41 16.70 0.52
Heparin 4.04 0.13 6.43 0.16 15.36 0.75
Indomethacin 3.74 0.04 6.72 0.14 15.96 0.77
Aspirin 3.91 0.08 7.02 0.12 15.64 0.61
Heparin and 4.06 0.29 6.33 0.36 14.80 1.13
indomethacin
Heparin and 4.75 0.27 7.30 0.20 14.77 0.79
aspirin
Reproduced with permission from Susic D, Mandal AK, Radujkovic G,
Kentera D, JLab Clin Med 111:63—72, 1988.
characterized by a marked decrease in total peripheral resistance
and a reciprocal increase in cardiac output. Other investigators
have confirmed this antihypertensive effect of heparin in stroke-
prone SHR [34] and renal ablation hypertensive rats [35]. The
decrease in blood pressure is accompanied by a parallel decrease
in hematocrit, suggesting a causal relationship between these two
effects. Table 1 illustrates that this decrease in hematocrit was not
due to changes in blood volume. However, no significant blood
pressure response is observed in heparin treated normotensive
rats, despite a similar hematocrit decrease, as that seen in SHR
[5—7]. This lack of relationship between hematocrit and blood
pressure in the normotensive strain of rat tends to preclude a
major role of hematocrit in the antihypertensive effect of heparin.
In another study, SHR showed no blood pressure response
following an acute decrease in hematocrit [36]. In this study, when
regression analysis was done between hematocrit and total pe-
ripheral resistance in SHR and normotensive control rats, we
observed that in SHR, unlike the normotensive controls, a
decrease in hematocrit of about 20% results in a fall of twice as
much total peripheral resistance and consequently, a decrease in
blood pressure. This difference in blood pressure response to
acute and chronic hematocrit manipulations in hypertensive rats
could be due to some other mechanisms than viscosity changes.
Two studies may shed some light in our understanding of this
obscure relationship between hematocrit and blood pressure. In
one study, it was shown that endothelin-1 (ET-1) induces a
dose-dependent release of endothelium-derived nitric oxide
(EDNO), and this effect is obliterated by removal of endothelium
or infusion of oxyhemoglobin [37]. In another study, it has been
shown that hemoglobin binds EDNO and reduces its level [38].
Therefore, a tangential relationship may exist between lowering
hematocrit and vascular endothelial cell function of heparin, in
which low hematocrit can enhance the release, andior effects of
vasodilatory substances released by heparin.
Plasma renin activity (PRA), measured by angiotensin I level, is
elevated in both heparin treated SHR and its normotensive
controls. Although the exact mechanism for elevation of PRA and
its significance in the overall blood pressure lowering effect of
heparin are unknown, an intriguing observation has been reported
by our group [7]. This study showed that SHR treated daily with
a combination of subcutaneous heparin and oral angiotensin-
converting enzyme inhibitor, captopril, had significantly greater
reductions of blood pressure than did SHR treated with heparin
o captopril alone. This may represent an additive effect, or
heparin could potentiate the effect of captopril by acting on a
common pathway.
We have also noted that SHR treated with a prostaglandin
(PG) synthesis inhibitor (indomethacin, meclofenamate or aspi-
rin) along with daily heparin showed much greater decreases in
systolic, diastolic and mean arterial pressure than the decreases
caused by heparin alone. These pressor changes were accompa-
nied by parallel changes in total peripheral resistance [7]. How-
ever, plasma PGI2, PGF2 alpha, as well as thromboxane B2 and
urinary kallikrein levels in heparin treated SHR and normotensive
controls, showed no consistent changes [39]. All these findings
suggest that the PG cascade is an unimportant mechanism for the
antihypertensive effect of heparin.
Elucidation of potential mechanisms of the antihypertensive
effect of heparin
The mechanism of heparin's blood pressure lowering effect is
not yet fully elucidated, although a number of the components
involved in this process have been defined. These components are
presented in Figure 1. This figure illustrates our view that the
antihypertensive effect of heparin may be mediated by two
interconnected mechanisms: (1) endothelial cell mediated vasodi-
lation; (2) blunted vascular smooth muscle cell (VSMC) contrac-
tility.
Fundamentally, heparin's effect in lowering systemic blood
pressure appears to be mediated through a series of secondary
signaling pathways, such as ET-1 and EDNO or cyclic 3'—S'
guanosine monophosphate (cGMP) and directly involves vascular
endothelial cells. Heparin then is the primary signal and ET-1 and
EDNO or cGMP are secondary signals. In this context, it is of
interest to point out that after injection, heparin is rapidly
removed from the circulation by the endothelial cells. Direct
measurement shows that the concentration of heparin in the
endothelium is 100 times that in the plasma [16]. Some of these
secondary signals (EDNO or cGMP) are then assumed or have
been shown to affect the vascular smooth muscle cells in a manner
that reduces cellular contraction and enhances vascular dilation
[40]. This is postulated to reduce vascular constriction and so
lowers the systemic blood pressure.
Among the demonstrated blood pressure lowering effects of
heparin at the cellular level are: inhibition of ET-1 and increased
EDNO release by endothelial cells, both growth promotioni
inhibition of endothelial cells in culture, inhibition of VSMC
proliferation and blunted VSMC contractility. These effects may
all function in an interconnected network or they may represent
disparate mechanisms which function independently. Our current
view is that endothelial cell function is an overall pathway by
which heparin contributes to regulation of vascular reactivity and
blood pressure control in a complimentary fashion.
The findings obtained in our laboratories and reviewed here can
provide an insight into mechanisms of the vasodepressor effects of
heparin. Thus, bolus injection of ET-1 in SHR after daily treat-
ment with subcutaneous heparin for four weeks produced an
initial maximal vasodilatory response which followed a blunted
pressor response. Both these vasodilatory and pressor responses
in heparin treated SHR were significantly different than those
observed in untreated SHR and heparin treated and untreated
normotensive Wistar Kyoto (WKY) rats [8]. The exaggerated
initial vasodilation observed in heparin treated SHR compared to
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Fig. I. Heparin has been shown to affect the vascular wall and exert its salutaty effects on blood pressure by acting on the endothelium and vascular smooth
muscle cells. Thrombin is a potent agonist for ET-i production. Heparin potently suppresses PT-i production, possibly by inhibiting thrombin as well
as independently down regulating PT-i mRNA. Heparin has no effect on PT-i peptide release or PT-i mRNA expression in the presence of PDNO
inhibitor, LNMMA in cultured cell medium. Heparin stimulates PDNO and/or cOMP, which may be further enhanced by low hematocrit. Heparin
supprcsses PT-i induced as well as angiotensin II stimulated intracellular calcium mobilization in VSMCs. Heparin also markedly suppresses 1P3 which
is a second messenger of calcium. Inhibition of caleium-calmodulin complex formation decreases contractile properties including force, stiffness and
maximal velocity. Thus, vasodilation and decreased VSMC contractility together can result in lowering of blood pressure. Heparin also inhibits PT-i
production in glomerular mesangial cells. This renal effect may result in decreased renal vascular resistance and add to the overall antihypertensive effect
of heparin. Abbreviations and symbols are: PT, Endothelin; PDNO, Pndothelium-derived nitric oxide; cGMP, Cyclic 3'—5' guanosine monophosphate;
[Ca2], Intracellular calcium; 1P3, Inositol 1,4,5 trisphosphate; VSMC, Vascular smooth muscle cell; PKC, Protein kinase C; (+), Stimulation; (—),
Inhibition; ----, Possibly additive.
all other groups may be due to excessive release of PDNO. The
latter could conceivably also blunt the pressor response to PT-i
infusion.
In recent studies, we have shown that heparin markedly sup-
presses PT-i release in cultured rat aortic, and human umbilical
vein (HUV) endothelial cells [41, 42]. Further, in cultured HUV
endothelial cells, heparin has been shown to suppress both basal
and thrombin-stimulated PT-i mRNA expression parallel with a
decrease in PT-i peptide release in a dose-dependent manner
[41]. Similarly, suppression of PT-i release and PT-i mRNA
expression in a dose- and time-dependent fashion by heparin was
also found in cultured aortic endothelial cells from SHR and
WKY rats [42]. These suppressive effects were significantly (P C
O.Oi) more marked in cells from SHR than in WKY rats. Other
investigators have also shown suppressive effects of heparin on
thrombin-stimulated PT-i production in cultured bovine and
porcine endothelial cells [43, 44].
These findings illustrate that heparin apparently functions in a
potentially regulatory role with regard to thrombin-stimulated
PT-i expression in endothelial cells from several species. There-
fore, these findings suggest that endothelial cell response to
heparin is broad-based, ubiquitous and is not species specific.
In addition, heparin has been shown to markedly enhance
thrombin-stimulated cOMP production in cultured HUV endo-
thelial cells [4i]. Both these intracellular effects of heparin on
PT-i and cGMP production were completely abolished by pre-
treatment of cultured cells with N° monomethyl L-arginine
(LNMMA), suggesting that heparin stimulates cOMP production
through an PDNO-mediated pathway. Furthermore, in the pres-
ence of LNMMA, heparin did not affect either basal or thrombin
stimulated PT-i mRNA expression and PT-i peptide release.
Therefore, these results suggest that heparin suppresses' PT-I
production through an PDNO-cGMP mediated pathway [4i].
L.NMMA is an analog of L-arginine, and by inhibition of PDNO
it abrogates the initial vasodilator response of PT-i [45, 46].
Further, heparin has been shown to enhance production of
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N02/N03 in cultured HUV endothelial cells [41]. All these
findings indicate that the effect of heparin is endothelium-depen-
dent. It is possible that heparin acts primarily on an inducible
nitric oxide synthetase which results in increased production of
nitric oxide and/or cGMP. Thus, assay of plasma levels of ET-1
and cGMP could be a marker of heparin's intracellular effects.
Endothelin affects intracellular mechanisms in VSMCs and may
initiate the vasoconstrictive process. These intracellular mecha-
nisms are (1) intracellular calcium mobilization, [Ca2]; (2)
phophatidylinositol hydrolysis. ET-1 probably causes vasocon-
striction through such intracellular calcium mobilization and/or
protein kinase C (PKC) dependent pathways in VSMCs [47].
Intracellular calcium is a primary messenger that binds to the
intracellular receptor protein calmodulin. In VSMCs, Ca2t'calm-
odulin complexes activate myosin light chain kinase, which phos-
phorylates the regulatory light chain of myosin. This phosphory-
lation reaction increases the actin-activated Mg ATPase activity of
myosin and is associated with increases in contractile properties
including force, stiffness, and maximal velocity [48]. Heparin
significantly reduced ET-l stimulated [Ca2]1, as well as produc-
tion of its second messenger, inositol 1,4,5 trisphosphate in
cultured VSMCs. These effects were more pronounced in SHR
than in WKY rats [49]. Other investigators have shown that
heparin suppresses angiotensin IT-stimulated intracellular calcium
mobilization in VSMCs [491. Therefore, by means of inhibition of
ET-1 and angiotensin II mediated [Ca2] mobilization, heparin
has the potential to down-regulate the VSMC contractile pathway
and thereby cause vascular relaxation.
The direct effect of heparin on VSMC activity has been
examined by several groups [50—54]. In these studies, heparin has
been shown to directly inhibit VSMC proliferation in a dose-
dependent manner. This VSMC antiproliferative effect has also
been reported in vitro with commercial heparin preparations [55].
In earlier studies, this group reported that heparin treatment had
a significant effect on histologic findings associated with hyperten-
sion. In particular, heparin treated and untreated SHR were
examined for renal vascular pathology. Principal changes in
untreated SHR involved marked arteriolar smooth muscle cell
hyperplasia to the point of virtual occlusion of the arteriolar
lumen and significant necrosis with formation of thrombi in other
arterioles. These changes were substantially less notable in hepa-
rin treated animals [4, 7]. Although the exact relationship of this
antiproliferative effect of heparin to its blood pressure lowering
function is still undefined, changes noted in VSMCs within the
vessel wall, effects on in vitro endothelial cell cultures, and other
studies, relate well to heparin's apparent biological function in
blood pressure regulation.
In cultured rat mesangial cells, heparin has been shown to
inhibit phorbol myristate acetate (PKC activator) stimulated ET-1
secretion. This inhibition is completely abolished in PKC-depleted
mesangial cells. Heparin also shows inhibition of ET-1 production
in a concentration-related fashion when stimulated by agonists,
including arginine vasopressin and platelet derived growth factor
in rat cultured mesangial cells [56]. Previous investigators have
also shown that heparin inhibits the proliferation of glomerular
mesangial cells [57, 58]. Thus, heparin treatment by its inhibitory
effects on the production of ET-1 in mesangial cells may contrib-
ute to the attenuation of hypertension [56].
These and other studies concerning the effect of heparin and
heparan sulfate on endothelial cells and VSMCs illustrate several
major points surrounding the interactive role of these vascular
components. First, heparin directly affects the endothelium which
responds by modified intracellular release of the vasoactive sub-
stances, that is, ET-1 and EDNO or cOMP. Second, there appears
to be an interactive signaling pathway or pathways between the
endothelium and the VSMC of the underlying intima. Third,
VSMCs apparently respond in part to signals from the endothe-
hum by producing a cell-surface heparan sulphate which under-
goes cleavage and then functions as an antiproliferative autocrine
signal [53].
Clinical perspective
By the analysis of our data and those of others, in a rather
realistic fashion, a reasonable premise can be made that heparin
most likely lowers blood pressure by the release of vasodilator
cGMP and/or EDNO. These vasodilator substances will reduce
the vascular reactivity and blunt pressor response to vasoconstric-
tor substances including ET-1, angiotensin II and norepinephrine.
Nitroglycerine is a potent vasodilator, an activator of soluble
guanylate cyclase and markedly reduces thrombin-stimulated
ET-1 production in cultured endothelial cells [45]. Heparin's
effects are similar to nitroglycerin; therefore, heparin can be
considered as a potent vasodilator. Initially enhanced release of
cGMP or EDNO may subsequently suppress ET-1 production by
a cGMP-dependent pathway, as suggested by other investigators
[59]. The suppression of ET-1 production will most likely decrease
VSMC contractility and increase vascular wall refractoriness to
other vasoconstrictor substances. Heparin has been shown to have
affinity for endothelial cells and selectively reaches high concen-
tration in these cells [60, 61]. The precise mechanism by which
exogenous heparin gains access into the endothelial cells is
unknown. Whether heparin diffuses through basal lamina of
endothelial cell or the effect is exerted via signal transduction
from the circulation is not yet established.
Differences in responses of SHR and normotensives are sum-
marized in Table 2. Although the hematocrit and ET-1 changes
between hypertensive and normotensives may be similar, the
differences in blood pressure responses between these two strains
suggest a common intrinsic regulatory pathway for pressure
control, that is heparin. Heparin has displayed antiendothelin
effects in terms of release and its action in cultured cells from both
hypertensive as well as normotensive control rats. However, the
antiendothelin effect is more pronounced in hypertensive than in
normotensive control rat cells. Thus, this heparin-induced differ-
ence in cellular response coupled with differences in pressor
response between the hypertensive and normotensive rats suggest
that the vascular system in hypertensive rats is more sensitive to
exogenous heparin (Table 2). Whether this exaggerated sensitivity
of hypertensive vascular cells to exogenous heparin is due to a lack
of, or insensitivity to endogenous heparin, remains to be tested.
However, either abnormality related to endogenous heparin could
occur in relative or absolute form and express itself with variable
severity of increased vascular resistance and elevated blood
pressure.
Although the antihypertensive effect of heparin has been
documented in hypertensive rat models, how this experimental
finding can be extrapolated to elucidate the mechanisms of
essential hypertension is still unknown. However, this observation
is provocative for further investigation. This is especially impor-
tant, since human endothelial cells have shown responses to
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Table 2. Summaiy of heparin's effects in the rat
Normotensive Hypertensive
Untreated Treated Untreated Treated
BP, mm 110.3 3.1 108,2 3.2 182.8 2.9 161.1 3.5
Hg
HTC, % 43.3 0.7 34.9 1.2 48.2 0.8 37.6 1.7
ET-1, P1 2.1 0.057 1.8 0.047 2.0 0.052 1.5 0.055
pM
ET-1, CC 7.0 0.18 0.05 0.009 7.9 0.35 0.04 0.005
pMCA2 % 100 5 75 10 100 5 35 10
1P3, % 100 5 85 10 100 5 65 10
PGI2, 32±2 36±3 35±3 36±4
pg/ml
Path — — +++
Data summarized from references cited in the text. Abbreviations are:
BP, Blood pressure; HTC, Hematocrit; ET-1, Endothelin4, P1, Plasma;
CC, Cultured endothelial cells; CA2, Calcium; 1P3, Inositol trisphos-
phate; PGI2, prostacyclin; Path, Histopathology.
a Heparin dose of 100 U/mI, value listed is % of control level.
exogenous heparin similar to those demonstrated in rat aortic
endothelial cells.
In summary, these studies have improved our understanding of
endothelial cell expression of vasoactive substances modified by
heparin treatment and helped to establish the conceptual frame-
work within which to understand heparin's effect on hypertension.
Among the potential antihypertensive effects of heparin which
have been documented are: decreased endothelial cell expression
of ET-1 protein and mRNA, as well as increased endothelial cell
release of nitric oxide and cGMP. These observations have lead to
development of several new perspectives on the overall question
of heparin's role in blood pressure control, including the model
proposed in this review. This model illustrates the potentially
central role of heparin in vasoregulatory control of blood pres-
sure. Further investigations are underway in our laboratories to
elucidate the role of heparin in the pathophysiology of hyperten-
sion.
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